glp 1 agonist retatrutide triple gip glp-1 glucagon phase 2 obesity trial 🧬 The Evolution of Weight Retatrutide for weight loss: Study

For Research Purposes Only: This product is sold strictly for laboratory research use only and must be handled accordingly

Tirzepatide is the agonist of GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor, which can reduce body weight and improve cardiac metabolism by subcutaneous injection once a week (Jastreboff et al 2022)

Currently, only two GLP-1s are approved by the FDA to treat obesity: Wegovy and Saxenda (liraglutide)

Causes dry mouth and sometimes blurred vision but extremely effective for some patients

If you experience throat discomfort or other adverse effects, several strategies may help